New Patient Access Programs
Many cancer centers operate at or close to full capacity and have difficulty scheduling patient appointments in a timely manner. Delayed appointments may directly impact patient outcomes when a patient is unable to seek treatment. A delayed appointment may also cause additional distress for patients who are anxious to schedule treatment.
Category
  • Best Practices
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Challenging Case Review: Non-Small Cell Lung Cancer
As a result of the therapeutic advances and clinical research affecting the management of patients with non-small cell lung cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Management of Pain in Patients with Cancer
Pain is commonly experienced by patients with cancer, and effective treatment of pain is a necessary component of supportive care for patients with cancer. Optimal treatment of cancer pain can be complex, including a combination of pharmacologic and nonpharmacologic therapies and coordination of patient comorbidities, including opioid use disorder.
Category
  • Pain
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Neoadjuvant Treatment Approaches for Stage II-III Rectal Cancer
The promising pCR data for total neoadjuvant therapy and dostarlimab and the impact these treatment strategies may have for the watch-and-wait approach have exciting implications for patients who are not candidates for surgery or for those who wish to avoid surgical morbidity.
Category
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Prophylaxis for Cancer-Associated Venous Thromboembolic Disease
VTE is common among patients with cancer and represents an appreciable risk, with associated morbidity and mortality. Accurate VTE risk assessment is important in identifying appropriate candidates for VTE prophylaxis and at times can prevent unnecessary use of anticoagulants. Selecting a suitable regimen in these patients requires guidance from physicians with experience treating various oncology subpopulations.
Category
  • Venous Thromboembolic Disease
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
NCCN Guidelines® for Central Nervous System Cancers: Updates in the Treatment of Adult Patients with Glioma
With the use of genetic and molecular testing, gliomas can be differentiated more accurately in terms of prognosis and, in some instances, response to different therapies. The updated WHO classification of tumors of the central nervous system (CNS) takes into account the importance of molecular data for accurately diagnosing CNS tumors. Detection of genetic or epigenetic alterations could expand clinical trial options for a patient with a brain tumor.
Category
  • Central Nervous System Cancers
  • Glioma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Plenary Session: Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors
Sleep, fatigue and cognitive function are important in improving quality of life in cancer survivors. These issues are often not addressed appropriately and further education and awareness can promote increased quality of life in cancer survivors.
Category
  • Supportive Care Topics
  • Survivorship
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Updates in the Treatment of Metastatic Colorectal Cancer
Targeted therapy approaches for mCRC continue to evolve as new data helps define how to best improve outcomes. Decisions regarding treatment for patients with mCRC require that clinicians be familiar with existing and new targeted therapies as well as the most effective and tolerable combination regimens.
Category
  • Colorectal Cancer
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
NCCN Guidelines® Insights - Breast Cancer, Version 4.2023
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer address all aspects of management for breast cancer. The treatment landscape of metastatic breast cancer is evolving constantly.
Category
  • Breast Cancer
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages